34 research outputs found

    Ampliação da sobrevida em crianças com AIDS no Brasil: resultados do segundo estudo nacional de 1999 a 2002

    Get PDF
    The objective of this study is to characterize survival in children with AIDS diagnosed in Brazil between 1999-2002, compared with the first national study (1983-1998). This national retrospective cohort study examined a representative sample of Brazilian children exposed to HIV from mother-to-child transmission and followed through 2007. The survival probability after 60 months was analyzed by sex, year of birth and death, clinical classification, use of antiretroviral therapy (ART) and prophylaxis for opportunistic diseases. 920 children were included. The survival probability increased: comparing cases diagnosed before 1988 with those diagnosed from 2001-2002 it increased by 3.5-fold (from 25% to 86.3%). Use of ART, initial clinical classification, and final classification were significant (p < 0.001) predictors of survival. Issues regarding quality of records and care were identified. The results point to the success of the Brazilian policy of providing ART. The improvement of clinical status contributes to quality of life, while indicating challenges, particularly practices to improve long-term care.Este estudo caracteriza a sobrevida em crianças com AIDS no Brasil entre 1999-2002, contextualizando com o primeiro estudo nacional (1983-1998). Trata-se de coorte histórica, com crianças expostas ao HIV por transmissão vertical e acompanhadas até 2007. A probabilidade de sobrevivência em 60 meses foi analisada segundo sexo, ano de nascimento e de óbito, classificação clínica, uso de terapia antirretroviral (TARV) e de profilaxia para doenças oportunistas. No total, 920 crianças foram incluídas. A probabilidade de sobrevivência foi ampliada 3,5 vezes nos dois períodos avaliados, passando de 25% antes de 1988 para 86,3% no período de 2001-2002. Uso de TARV, classificação clínica inicial e atual/final foram preditores que influíram significativamente (p < 0,001) para a ampliação da sobrevida. Os resultados deste estudo indicam o sucesso da política brasileira para a abordagem das crianças infectadas com HIV. A melhora do estado clínico contribuiu para melhora da qualidade de vida, mas sinaliza-se para a necessidade de incorporação de práticas pautadas na integralidade do cuidado

    Technical performance of a lateral flow immunoassay for detection of anti-SARS-CoV-2 IgG in the outpatient follow-up of non-severe cases and at different times after vaccination: comparison with enzyme and chemiluminescent immunoassays

    Get PDF
    This study assessed the technical performance of a rapid lateral flow immunochromatographic assay (LFIA) for the detection of anti-SARS-CoV-2 IgG and compared LFIA results with chemiluminescent immunoassay (CLIA) results and an in-house enzyme immunoassay (EIA). To this end, a total of 216 whole blood or serum samples from three groups were analyzed: the first group was composed of 68 true negative cases corresponding to blood bank donors, healthy young volunteers, and eight pediatric patients diagnosed with other coronavirus infections. The serum samples from these participants were obtained and stored in a pre-COVID-19 period, thus they were not expected to have COVID-19. In the second group of true positive cases, we chose to replace natural cases of COVID-19 by 96 participants who were expected to have produced anti-SARS-CoV-2 IgG antibodies 30-60 days after the vaccine booster dose. The serum samples were collected on the same day that LFIA were tested either by EIA or CLIA. The third study group was composed of 52 participants (12 adults and 40 children) who did or did not have anti-SARS-CoV-2 IgG antibodies due to specific clinical scenarios. The 12 adults had been vaccinated more than seven months before LFIA testing, and the 40 children had non-severe COVID-19 diagnosed using RT-PCR during the acute phase of infection. They were referred for outpatient follow-up and during this period the serum samples were collected and tested by CLIA and LFIA. All tests were performed by the same healthcare operator and there was no variation of LFIA results when tests were performed on finger prick whole blood or serum samples, so that results were grouped for analysis. LFIA’s sensitivity in detecting anti-SARS-CoV-2 IgG antibodies was 90%, specificity 97.6%, efficiency 93%, PPV 98.3%, NPV 86.6%, and likelihood ratio for a positive or a negative result were 37.5 and 0.01 respectively. There was a good agreement (Kappa index of 0.677) between LFIA results and serological (EIA or CLIA) results. In conclusion, LFIA analyzed in this study showed a good technical performance and agreement with reference serological assays (EIA or CLIA), therefore it can be recommended for use in the outpatient follow-up of non-severe cases of COVID-19 and to assess anti-SARS-CoV-2 IgG antibody production induced by vaccination and the antibodies decrease over time. However, LFIAs should be confirmed by using reference serological assays whenever possible

    A Brazilian university hospital position regarding transplantation criteria for HIV-positive patients according to the current literature

    Get PDF
    Human immunodeficiency virus (HIV) infection was considered a contraindication for solid organ transplantation (SOT) in the past. However, HIV management has improved since highly active antiretroviral therapy (HAART) became available in 1996, and the long-term survival of patients living with HIV has led many transplant programs to reevaluate their policies regarding the exclusion of patients with HIV infection. Based on the available data in the medical literature and the cumulative experience of transplantation in HIVpositive patients at our hospital, the aim of the present article is to outline the criteria for transplantation in HIVpositive patients as recommended by the Immunocompromised Host Committee of the Hospital das Clı´nicas of the University of Sa˜o Paulo

    Cytomegalovirus infection in transplant recipients

    Get PDF
    Cytomegalovirus infection is a frequent complication after transplantation. This infection occurs due to transmission from the transplanted organ, due to reactivation of latent infection, or after a primary infection in seronegative patients and can be defined as follows: latent infection, active infection, viral syndrome or invasive disease. This condition occurs mainly between 30 and 90 days after transplantation. In hematopoietic stem cell transplantation in particular, infection usually occurs within the first 30 days after transplantation and in the presence of graft-versus-host disease. The major risk factors are when the recipient is cytomegalovirus seronegative and the donor is seropositive as well as when lymphocyte-depleting antibodies are used. There are two methods for the diagnosis of cytomegalovirus infection: the pp65 antigenemia assay and polymerase chain reaction. Serology has no value for the diagnosis of active disease, whereas histology of the affected tissue and bronchoalveolar lavage analysis are useful in the diagnosis of invasive disease. Cytomegalovirus disease can be prevented by prophylaxis (the administration of antiviral drugs to all or to a subgroup of patients who are at higher risk of viral replication) or by preemptive therapy (the early diagnosis of viral replication before development of the disease and prescription of antiviral treatment to prevent the appearance of clinical disease). The drug used is intravenous or oral ganciclovir; oral valganciclovir; or, less frequently, valacyclovir. Prophylaxis should continue for 90 to 180 days. Treatment is always indicated in cytomegalovirus disease, and the gold-standard drug is intravenous ganciclovir. Treatment should be given for 2 to 3 weeks and should be continued for an additional 7 days after the first negative result for viremia

    Differences in children and adolescents with SARS-CoV-2 infection: a cohort study in a Brazilian tertiary referral hospital

    Get PDF
    OBJECTIVES: To compare demographic/clinical/laboratory/treatments and outcomes among children and adolescents with laboratory-confirmed coronavirus disease 2019 (COVID-19). METHODS: This was a cross-sectional study that included patients diagnosed with pediatric COVID-19 (aged &lt;18 years) between April 11, 2020 and April 22, 2021. During this period, 102/5,951 (1.7%) of all admissions occurred in neonates, children, and adolescents. Furthermore, 3,962 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection samples were processed in patients aged &lt;18 years, and laboratory-confirmed COVID-19 occurred in 155 (4%) inpatients and outpatients. Six/155 pediatric patients were excluded from the study. Therefore, the final group included 149 children and adolescents (n=97 inpatients and 52 outpatients) with positive SARS-CoV-2 results. RESULTS: The frequencies of sore throat, anosmia, dysgeusia, headache, myalgia, nausea, lymphopenia, pre-existing chronic conditions, immunosuppressive conditions, and autoimmune diseases were significantly reduced in children and adolescents (p&lt;0.05). Likewise, the frequencies of enoxaparin use (p=0.037), current immunosuppressant use (p=0.008), vasoactive agents (p=0.045), arterial hypotension (p&lt;0.001), and shock (p=0.024) were significantly lower in children than in adolescents. Logistic regression analysis showed that adolescents with laboratory-confirmed COVID-19 had increased odds ratios (ORs) for sore throat (OR 13.054; 95% confidence interval [CI] 2.750-61.977;&nbsp;p=0.001), nausea (OR 8.875; 95% CI 1.660-47.446;&nbsp;p=0.011), and lymphopenia (OR 3.575; 95% CI 1.355-9.430;&nbsp;p=0.010), but also had less hospitalizations (OR 0.355; 95% CI 0.138-0.916;&nbsp;p=0.032). The additional logistic regression analysis on patients with preexisting chronic conditions (n=108) showed that death as an outcome was significantly associated with pediatric severe acute respiratory syndrome (SARS) (OR 22.300; 95% CI 2.341-212.421;&nbsp;p=0.007) and multisystem inflammatory syndrome in children (MIS-C) (OR 11.261; 95% CI 1.189-106. 581;&nbsp;p=0.035). CONCLUSIONS: Half of the laboratory-confirmed COVID-19 cases occurred in adolescents. Individuals belonging to this age group had an acute systemic involvement of SARS-CoV-2 infection. Pediatric SARS and MIS-C were the most important factors associated with the mortality rate in pediatric chronic conditions with COVID-19

    Síndrome de Noonan : Noonan Syndrome

    Get PDF
    Introdução: A Síndrome de Noonan (SN) é uma doença de herança autossômica dominante, com incidência estimada de 1/1000 até 1/2500 nascidos vivos. A síndrome é frequentemente associada a defeitos cardíacos e uma grande variabilidade fenotípica. Apresentação do caso:&nbsp; Paciente do sexo masculino, 3 anos de idade e diagnóstico prévio de Comunicação Interatrial, corrigida cirurgicamente. No primeiro ano de vida, foram notadas alterações fenotípicas, como ptose palpebral, orelhas de implantação baixa, face triangular, tórax em escudo, pescoço curto e diagnóstico de sinusite crônica. Discussão: A anomalia congênita mais comum da SN é a estenose valvar pulmonar (54% dos casos) bastante relacionada à morbidade e à mortalidade da doença. As características fenotípicas podem incluir hipertelorismo, ptose palpebral, pescoço alado, baixa estatura, entre outros. A doença possui uma ampla variabilidade clínica e tem como diagnóstico diferencial a Síndrome de Costello e a Síndrome de Turner. O diagnóstico é realizado por meio de uma avaliação clínico-genética. Conclusão: O presente relato ressalta a importância do conhecimento em relação a SN para que sejam realizadas histórias clínicas completas e exames físicos minuciosos diante da suspeita clínica para fins de diagnóstico precoce, acompanhamento multidisciplinar e melhora do prognóstico

    Tumor glioneural difuso leptomeníngeo: Leptomeningeal diffuse glioneural tumor

    Get PDF
    Introdução: O tumor Glioneural Difuso Leptomeníngeo (DLGNT) é uma neoplasia primária rara do sistema nervoso central (SNC). Descrito pela Classificação dos Tumores do Sistema nervoso Central da OMS 2016 como sendo o tumor leptomeníngeo tipo oligodendroglial mais notável na infância. O prognóstico geralmente é ruim, e a média de sobrevida é de 15 meses. Apresentação do caso: Paciente do sexo masculino, 6 anos, previamente hígido, admitido no Hospital Evangélico de Goiás, após 20 dias de quadro inicial de cefaleia, vômitos, fotofobia, alteração sensorial e paraparesia moderada (pior à direita). Foi internado para investigação de meningite. Procedeu-se à biópsia e ao estudo imuno-histoquímico do material, que confirmaram o diagnóstico de DLGNT. Discussão: É uma doença rara, constituindo aproximadamente 1-3% de todos os tumores cerebrais em adultos e cerca de 3% dos ocorridos em crianças. Com um quadro clínico bastante inespecífico, com extensa quantidade de diagnósticos diferenciais a serem afastados. Para o tratamento não há consenso quanto a terapêutica radioterapia/quimioterapia e farmacológica adequada. Conclusão: A identificação precoce de DLGNT auxilia na seleção adequada de tratamentos específicos, contribuindo para um melhor prognóstico e melhora clínica do paciente. São necessários mais estudos para promover uma maior compreensão desta doença e consequentemente, melhora na qualidade de vida dos pacientes
    corecore